Analysis of distant cardiovascular events depending on the biomarker profile in patients with myocardial infarction

Acute coronary syndrome (ACS) and its complications is one of the main reasons of mortality and invalidation in the world. New biomarkers, such as ST2, NT-proBNP и Pentraxin-3 (Ptx-3) present much more opportunities in the diagnostics of diseases and risk of its development.

Aim. To investigate standards and “new” biomarkers in different variants of MI and cardiovascular events in 1 year after MI.

Material and methods. In 180 patients with MI (61,4±1,7 years) we determined the serum concentration of standard and “new” (ST2, NT-proBNP, Ptx-3) biomarkers in groups with Q/non-Q, STEMI and NSTEMI and the endpoints (MI, strokes, repeated hospitalizations and sudden deaths) in 1 year (384,3±21,2 days) after MI.

Results. Patients with Q-MI and STEMI had higher risk of unfavorable cardiovascular events (p<0,05). Ptx-3 >43,9 ng/ml was shown to be risk factor for sudden death (sensitivity 70,0%, specificity 52,9%), and >125,9±0,06 ng/ml (74,1% and 44,1%) — of recurrent MI.

Conclusion. NT-proBNP, ST2 and Ptx-3 showed prognostic value in the diagnostics of unfavorable cardiovascular endpoints.

1. The Demographic Yearbook of Russia. 2017: Statistical compilation/Rosstat. Moscow. 2017 pp.100-12. (In Russ.)

2. Jenkins WS, Roger VL, Jaffe AS. Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective. Am J Med. 2017;130(9):1112.e9-1112.e15. doi:10.1016/j.amjmed.2017.02.034.

3. Lupón J, de Antonio M, Galán A. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment. Mayo Clin Proc. 2013;88(3):234-43. doi:10.1016/j.mayocp.2012.09.016.

4. Matsubara J, Sugiyama S, Nozaki T, et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol. 2011;57(7):861-9. doi:10.1016/j.jacc.2010.10.018.

5. Magnussen C, Blankenberg S. Biomarkers for heart failure: small molecules with high clinical relevance. J Intern Med. 2018;283(6):530-43. doi:10.1111/joim.12756.

6. Braunwald E. Heart failure. JACC Heart Fail. 2013;1(1):1-20. doi:10.1016/j.jchf.2012.10.002.

7. Bayes-Genis A, Richards AM, Maisel AS, et al. Multimarker testing with ST2 in chronic heart failure. Am J Cardiol. 2015;115(7 Suppl):76B-80B. doi:10.1016/j.amjcard.2015.01.045.

8. Ky B, French B, Levy WC, et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ. Heart Fail. 2012;5(2):183-90. doi:10.1161/CIRCHEARTFAILURE.111.965020.

9. Editorial article. The third universal definition of myocardial infarction. Russ J Cardiol. 2013; (2s1): 3-16. (In Russ.)

10. Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109:2186-90. doi:10.1161/01.CIR.0000127958.21003.5A.

11. Villacorta H, Maisel AS. Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure. Arq Bras Cardiol. 2016;106(2):145-52. doi:10.5935/abc.20150151.

12. Bayes-Genis A, Januzzi JL, Gaggin HK, et al. ST2 pathogenetic profile in ambulatory heart failure patients. J Card Fail. 2015;21(4):355-61. doi:10.1016/j.cardfail.2014.10.014.

13. Sabatine MS, Morrow DA, Higgins LJ, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008;117(15):1936-44. doi:10.1161/CIRCULATIONAHA.107.728022.

14. Ehab KEl, Melegya EA, Badrb A, et al. Pentraxin 3 genotyping in relation to serum levels of pentraxin 3 in patients with acute ST-segment elevation myocardial infarction. Clinical Trials and Regulatory Science in Cardiology. 2016;13:6-13. doi:10.1016/j.ctrsc.2015.11.002.